Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare Biotechnology

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Retail investors didn’t even get the opportunity to vote re

<< Previous

Bullboard Posts

Next >>

Comment by Newinvestor68on Jul 20, 2020 11:09pm

123 Views

Post# 31294100

RE:RE:RE:RE:RE:Retail investors didn’t even get the opportunity to vote re

Please do not spread false information. They do not have BARDA funding. They COULD receive more funding. This is taken from the press release on their website.

An additional USD $69.9 million could be released to Salzman Group over the next 36 months, as developmental milestones are achieved.

<< Previous

Bullboard Posts

Next >>

Anaergia expands relationship with PepsiCo